SCHEMBL5216256

SCHEMBL5216256

CCOC(=O)c1csc(Nc2ncccc2Cl)n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.54
RAB9A P51151 6/20 0.54
SMN1; SMN2 Q16637 6/20 0.54
NPC1 O15118 5/20 0.54
MAPT P10636 4/20 0.54
CYP1A2 P05177 1/20 0.53
CYP2C19 P33261 1/20 0.53
LMNA P02545 3/20 0.53
MAPK1 P28482 2/20 0.53
ALDH1A1 P00352 2/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
TDP1 Q9NUW8 2/20 0.52
GAA P10253 2/20 0.51
HSP90AA1 P07900 2/20 0.51
MAOA P21397 2/20 0.51
MAOB P27338 2/20 0.51
ANO1 Q5XXA6 1/20 0.50
KDM4E B2RXH2 3/20 0.49
NPSR1 Q6W5P4 1/20 0.49
KDM1A O60341 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL789722 0.82 MAPT (0.73) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL5215470 0.82 RAB9A (0.50) RAB9ASMN1; SMN2NPC1MAPTLMNA
SCHEMBL525057 0.80 RAB9A (0.60) RAB9ASMN1; SMN2NPC1MAPTCYP1A2
SCHEMBL5213498 0.79 CYP1A2 (0.57) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL31507493 0.79 RAB9A (0.54) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL5218406 0.78 SMN1; SMN2 (0.60) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL5041112 0.77 EGFR (0.73) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL4789312 0.77 SMN1; SMN2 (0.69) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL525373 0.77 MAOA (0.64) EGFRRAB9ASMN1; SMN2NPC1MAPT
SCHEMBL191185 0.77 ALDH1A1 (0.53) EGFRRAB9ASMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
US-7265138-B2 Vanilloid receptor ligands and their use in treatments AMGEN INC. (US) 2007-09-04 US disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1818333-A1 Vanilloid receptor ligands and their use in treatments Amgen Inc. (US) 2007-08-15 EP disclosed
EP-1603905-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2005-12-14 EP disclosed
WO-2004072068-A1 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2004-08-26 WO disclosed
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157845-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 EGFR 446/4885RAB9A 1553/4885SMN1; SMN2 2416/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.